He will also become executive vice president at the group, with responsibility for the progression of the small molecules and biologics investigational medicines on AstraZeneca’s books through late-stage development to regulatory approval.
Bohen will report to Pascal Soriot, AstraZeneca’s chief executive officer. He joins the company on 15 September.
Bohen departed from his previous post as senior vice president of early development at Genentech to assume his new role at AstraZeneca.
In his time at Genentech, Bohen presided over preclinical and clinical development programmes across all therapy areas, including oncology, respiratory, and autoimmune diseases, to deliver trial-ready drug candidates to late-stage development.
Bohen was previously a clinical instructor in oncology at Stanford University School of Medicine before his move into the private sector at Genentech.